Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from NIH

NIH Awarded More Than 56,000 Grants in 2020. Just 2 Percent Were for Studying COVID.

More evidence that the public health bureaucracy dropped the ball when a once-in-a-generation pandemic hit.

Big US gene database has volunteers from all walks of life

Big US gene database has volunteers from all walks of life

Scientists are getting their first peek at the genes of nearly 100,000 Americans in what's considered a uniquely diverse genomic database

The Independent UK

Moderna Moves Forward With Second HIV Vaccine Trial

Moderna Moves Forward With Second HIV Vaccine Trial

Moderna Inc (NASDAQ:MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Moderna co-founder Robert Langer: ‘I wanted to use my chemical engineering to help people’

The celebrated US scientist and inventor on not being in it for the money, why diversity improves problem-solving, and his dedication to exercising

The Guardian - UK

NIH Discontinues COVID-19 Phase 3 Trial Assessing SAB Biotherapeutics' SAB-185

SAB Biotherapeutics Inc (NASDAQ:SABS) said that due to low hospitalization and death rates in the trial, the National Institutes of Health's (NIH) ACTIV-2 Program is discontinuing enrollment in its Phase 3 COVID-19 trial. SAB-185 was being assessed as part of Phase 3 ACTIV-2 master protocol evaluating treatments for COVID-19 in patients with…

The loophole to lower drug prices

A provision known as "march-in rights" lets the government intervene if drugs are being sold at unreasonable prices

Michael Hiltzik: The government could force a price cut for this prostate cancer drug by as much as 80%. Why hasn't it acted?

Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.

Los Angeles Times

inkl

Read news from The Economist, FT, and more,
with one subscription

ACHV: The Final Phase III Begins

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

The great gaslighting: how Covid longhaulers are still fighting for recognition

The great gaslighting: how Covid longhaulers are still fighting for recognition

People with long Covid face an uphill battle convincing skeptics their malady is real – but discrediting uncommon conditions is hardly a new phenomenon

The Guardian - US

On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial

On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial

SAB Biotherapeutics Inc (NASDAQ: SABS) has

1 … 18 19 20 21

People

John Vandermosten

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Silicon Valley Bank

National Institutes of Health

National Institute of Allergy and Infectious Diseases

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

321,444 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play